Recent announcements

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
2022
August
Press Release
8 Aug
2022

POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022

The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later this year by providing an overview of SPLASH’s trial design. Register online today at https://hub.pointbiopharma.com/controlarm

2022
July
Press Release
6 Jul
2022

POINT Biopharma to Participate in Upcoming Investor Conferences

POINT will participate in the following summer investor conferences:

2022
June
Press Release
21 Jun
2022

POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial

Mr. Horvath will lead the commercialization of POINT’s pipeline. He brings over a decade of experience in pharmaceutical commercialization, most recently as the VP and Head of Prostate Cancer Radioligand Therapy Franchise at Advanced Accelerator Applications (a Novartis Company).

2022
May
Press Release
19 May
2022

POINT Biopharma to Participate in Upcoming Investor Conferences

Today announced that the Company’s Chief Executive Officer, Dr. Joe McCann will participate in the following upcoming investor conferences.

2022
May
Press Release
16 May
2022

POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program

A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy.

2022
May
Press Release
13 May
2022

POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update

POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada for Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) targeted program; trial is expected to commence this summer.

2022
May
Press Release
5 May
2022

POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial

Clinical doses continue to be manufactured and shipped from the Company’s Indianapolis, Indiana facility

2022
April
Press Release
26 Apr
2022

First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial

POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada, and Europe. Sites initiated in France, Sweden, Netherlands, and the UK, with randomization in each expected this summer.